Updates are available Correction dated 2024-05-06
Click to view Correction: https://doi.org/10.1007/s00270-024-03733-w
-
Authors
Tong, T. M. L. http://orcid.org/0000-0002-7381-6858
Fiocco, M.
van Duijn-de Vreugd, J. J.
Lutjeboer, J.
Speetjens, F. M.
Tijl, F. G. J.
Sitsen, M. E.
Zoethout, R. W. M.
Martini, C. H.
Vahrmeijer, A. L.
van der Meer, R. W.
van Rijswijk, C. S. P.
van Erkel, A. R.
Kapiteijn, E.
Burgmans, M. C.
- License Information
-
More Information
Article History
Received: 25 October 2023
Accepted: 12 March 2024
First Online: 8 April 2024
Change Date: 6 May 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1007/s00270-024-03733-w
Declarations
:
: MB has received consultancy fees from Delcath Systems. EK has consultancy/advisory relationships with Bristol Myers Squibb, Novartis, Pierre Fabre, Immunocore, and Lilly and received research grants not related to this paper from Bristol Myers Squibb, Delcath, Novartis, and Pierre-Fabre. Not related to current work and paid to institute. The other authors declare no conflict of interest.
: Consent for publication was obtained for every individual person’s data included in the study.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
: Informed consent was obtained from all individual participants included in the study.
